We observed, that P2Et-treated mice had higher numbers of spleen conventional DCs (CD45+, CD220−, CD11c+) with increased surface expression of co-stimulatory molecules such as CD86, CD40, MHCII and CD70, suggesting that in vivo P2Et treatment actually enhances the immunogenicity of tumor cells (Figures 7a and b). The gene discussed is CD86; the disease is neoplasm.